RCKT Q3 2021 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$538M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$50M

Net Income

-$50M

EPS (Diluted)

$-0.79

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$32M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$530M

Total Liabilities

$45M

Stockholders' Equity

$486M

Cash & Equivalents

$246M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$50M	-$27M	-81.3%
Net Income	-$50M	-$29M	-72.3%